U.S. National Cancer Institute perspective on precision oncology
6 Jul 2018
U.S. National Cancer Institute perspective on precision oncology
Precision medicine in newly diagnosed breast cancer
Editor's Choice for June 2018
Expert insight: The basic medical understanding of neutropenia and general clinical considerations
MASCC 2018: Chemotherapy-induced neutropenia and the role of G-CSFs
CDK6 a transcriptional regulator in AML
ASCO 2018 conference round up
Treating CLL with obinutuzumab
Lymphoma guidelines in Venezuela
Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma
Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma
Interim results of RELEVANCE trial in follicular lymphoma